Chapter 5 : Epstein-Barr Virus

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Epstein-Barr Virus, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555819040/9781555819033_Chap05-1.gif /docserver/preview/fulltext/10.1128/9781555819040/9781555819033_Chap05-2.gif


Epstein-Barr virus (EBV), a gamma herpesvirus, is a ubiquitous cause of infection in humans worldwide ( ). Evidence of prior infection is present in adults throughout the world, with over 90% showing a serologic response. Exposure typically occurs early in life, with the majority of children in developing countries becoming seropositive by age 5. While onset of infection is delayed in areas with greater socioeconomic development, adults are almost uniformly positive. EBV is most commonly transmitted by contact with respiratory secretions, which promotes access and entry into the reticuloendothelial cells of the upper respiratory tree. While the primary target cell of EBV is the B lymphocyte, infection of a wider range of cell types can occur in immunocompromised hosts, particularly in those of epithelial lineage. Pharyngeal infection is followed by dissemination of virus throughout the body, with B lymphocytes as the primary target. The immune response to infection mounts steadily, with expansion of EBV-specific cytolytic T-cell clones eventually recognizing and controlling the primary infection. Control of EBV proliferation is signaled by a shift from lytic viral activity (marked by lytic proteins associated with cell destruction, such as BZLF1 and BRLF1) to a latent phenotype in an immortalized B lymphocyte pool, which provides a lifelong source of low-grade reactivation. Development of a serological response, with initial IgM and IgG to viral capsid antigen, followed by antibody to the EBV nuclear antigen developing months after infection, provides reliable markers for acute and chronic infection in immunocompetent hosts.

Citation: Nowalk A, Green M. 2016. Epstein-Barr Virus, p 127-134. In Hayden R, Wolk D, Carroll K, Tang Y (ed),

Diagnostic Microbiology of the Immunocompromised Host, Second Edition

. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.DMIH2-0011-2015
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


1. Cohen JI . 2000. Epstein-Barr virus infection. N Engl J Med 343 : 481 492.[PubMed] [CrossRef]
2. Green M,, Michaels MG . 2013. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. Am J Transplant 13( Suppl 3) : 41 54, quiz 54.[PubMed] [CrossRef]
3. Smets F,, Bodeus M,, Goubau P,, Reding R,, Otte JB,, Buts JP,, Sokal EM . 2000. Characteristics of Epstein-Barr virus primary infection in pediatric liver transplant recipients. J Hepatol 32 : 100 104.[PubMed] [CrossRef]
4. Hsu JL,, Glaser SL . 2000. Epstein-Barr virus-associated malignancies: epidemiologic patterns and etiologic implications. Crit Rev Oncol Hematol 34 : 27 53.[PubMed] [CrossRef]
5. Allen UD,, Preiksaitis JK , AST Infectious Diseases Community of Practice . 2013. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation. Am J Transplant 13( Suppl 4) : 107 120.[PubMed] [CrossRef]
6. Rasche L,, Kapp M,, Einsele H,, Mielke S . 2014. EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT. Bone Marrow Transplant 49 : 163 167.[PubMed] [CrossRef]
7. Green M,, Webber S . 2003. Posttransplantation lymphoproliferative disorders. Pediatr Clin North Am 50 : 1471 1491.[PubMed] [CrossRef]
8. Ramos E,, Hernández F,, Andres A,, Martínez-Ojinaga E,, Molina M,, Sarría J,, Lopez-Santamaria M,, Prieto G . 2013. Post-transplant lymphoproliferative disorders and other malignancies after pediatric intestinal transplantation: incidence, clinical features and outcome. Pediatr Transplant 17 : 472 478.[PubMed] [CrossRef]
9. Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients (SRTR) . 2012. OPTN/SRTR 2010 Annual Data Report. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation. Am J Transplant 12( Supplement 1) : 1156.
10. Lau AH,, Soltys K,, Sindhi RK,, Bond G,, Mazariegos GV,, Green M . 2010. Chronic high Epstein-Barr viral load carriage in pediatric small bowel transplant recipients. Pediatr Transplant 14 : 549 553.[PubMed] [CrossRef]
11. Green M,, Soltys K,, Rowe DT,, Webber SA,, Mazareigos G . 2009. Chronic high Epstein-Barr viral load carriage in pediatric liver transplant recipients. Pediatr Transplant 13 : 319 323.[PubMed] [CrossRef]
12. García-Cadenas I,, Castillo N,, Martino R,, Barba P,, Esquirol A,, Novelli S,, Orti G,, Garrido A,, Saavedra S,, Moreno C,, Granell M,, Briones J,, Brunet S,, Navarro F,, Ruiz I,, Rabella N,, Valcárcel D,, Sierra J . 2015. Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab. Bone Marrow Transplant 50 : 579 584.[PubMed] [CrossRef]
13. Pinana JL,, Sanz J,, Esquirol A,, Martino R,, Picardi A,, Barbas P,, Parody R,, Gayoso J,, Montesinos P,, Guidi S,, Terol MJ,, Moscard F,, Solano C,, Arcese W,, Sanz MA,, Sierra J,, Sanz G On behalf of GETH GITMO Groups . 2015. Umbilical cord blood transplantation in adults with advanced hodgkin’s disease: high incidence of post-transplant lymphoproliferative disease. Eur J Haematol 96 : 128 135.[PubMed] [CrossRef]
14. Chandrakasan S,, Filipovich AH . 2013. Hemophagocytic lymphohistiocytosis: advances in pathophysiology, diagnosis, and treatment. J Pediatr 163 : 1253 1259.[PubMed] [CrossRef]
15. Pinzone MR,, Berretta M,, Cacopardo B,, Nunnari G . 2015. Epstein-Barr virus- and Kaposi sarcoma-associated herpesvirus-related malignancies in the setting of human immunodeficiency virus infection. Semin Oncol 42 : 258 271.[PubMed] [CrossRef]
16. Allen U,, Preiksaitis J , AST Infectious Diseases Community of Practice . 2009. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients. Am J Transplant 9( Suppl 4) : S87 S96.[PubMed] [CrossRef]
17. Loechelt BJ , , et al . 2014. Screening and monitoring for infectious complications when immunosuppressive agents are studied in the treatment of autoimmune disorders. J Pediatric Infect Dis Soc. [PubMed]
18. Worth A,, Conyers R,, Cohen J,, Jagani M,, Chiesa R,, Rao K,, Goulden N,, Veys P,, Amrolia PJ . 2011. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation. Br J Haematol 155 : 377 385.[PubMed] [CrossRef]
19. Juvonen E,, Aalto S,, Tarkkanen J,, Volin L,, Hedman K,, Ruutu T . 2007. Retrospective evaluation of serum Epstein Barr virus DNA levels in 406 allogeneic stem cell transplant patients. Haematologica 92 : 819 825.[PubMed] [CrossRef]
20. Preiksaitis JK,, Pang XL,, Fox JD,, Fenton JM,, Caliendo AM,, Miller GG , American Society of Transplantation Infectious Diseases Community of Practice . 2009. Interlaboratory comparison of Epstein-Barr virus viral load assays. Am J Transplant 9 : 269 279.[PubMed] [CrossRef]
21. Fryer JF,, Heath AB,, Wilkinson DE,, Minor PD and the Collaborative Study Group . 2011. Collaborative study to evaluate the proposed 1st WHO International Standard for Epstein-Barr Virus (EBV) for nucleic acid amplification (NAT)-based assays. World Health Organization, Geneva, Switzerland. http://apps.who.int/iris/bitstream/10665/70781/1/WHO_BS_2011.2172_org.pdf.
22. Michelson P,, Watkins B,, Webber SA,, Wadowsky R,, Michaels MG . 2008. Screening for PTLD in lung and heart-lung transplant recipients by measuring EBV DNA load in bronchoalveolar lavage fluid using real time PCR. Pediatr Transplant 12 : 464 468.[PubMed] [CrossRef]
23. Bingler MA,, Feingold B,, Miller SA,, Quivers E,, Michaels MG,, Green M,, Wadowsky RM,, Rowe DT,, Webber SA . 2008. Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children. Am J Transplant 8 : 442 445.[PubMed] [CrossRef]
24. Preiksaitis J, . 2010. Epstein-Barr viral load testing: role in the prevention, diagnosis and management of posttransplant lymphoproliferative disorders, p 45 68. In Dharnidharka VR,, Green M,, Webber S (ed), Post-Transplant Lymphoproliferative Disorders. Springer, New York. [CrossRef]
25. Rowe DT,, Qu L,, Reyes J,, Jabbour N,, Yunis E,, Putnam P,, Todo S,, Green M . 1997. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol 35 : 1612 1615.[PubMed]
26. Tsai DE,, Douglas L,, Andreadis C,, Vogl DT,, Arnoldi S,, Kotloff R,, Svoboda J,, Bloom RD,, Olthoff KM,, Brozena SC,, Schuster SJ,, Stadtmauer EA,, Robertson ES,, Wasik MA,, Ahya VN . 2008. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am J Transplant 8 : 1016 1024.[PubMed] [CrossRef]
27. Wadowsky RM,, Laus S,, Green M,, Webber SA,, Rowe D . 2003. Measurement of Epstein-Barr virus DNA loads in whole blood and plasma by TaqMan PCR and in peripheral blood lymphocytes by competitive PCR. J Clin Microbiol 41 : 5245 5249.[PubMed] [CrossRef]
28. Chowdhury FU,, Sheerin F,, Bradley KM,, Gleeson FV . 2009. PET/CT staging and response evaluation of post-transplantation lymphoproliferative disease (PTLD). Clin Nucl Med 34 : 386 387.[PubMed] [CrossRef]
29. Harris NL,, Jaffe ES,, Diebold J,, Flandrin G,, Muller-Hermelink HK,, Vardiman J,, Lister TA,, Bloomfield CD . 2000. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 13 : 193 207.[PubMed] [CrossRef]
30. Young L,, Alfieri C,, Hennessy K,, Evans H,, O'Hara C,, Anderson KC,, Ritz J,, Shapiro RS,, Rickington A,, Kieff E,, Cohen JL . 1989. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 321 : 1080 1085.[PubMed] [CrossRef]
31. Macedo C,, Zeevi A,, Bentlejewski C,, Popescu I,, Green M,, Rowe D,, Smith L,, Webber S,, Metes D . 2009. The impact of EBV load on T-cell immunity in pediatric thoracic transplant recipients. Transplantation 88 : 123 128.[PubMed] [CrossRef]
32. Smets F,, Latinne D,, Bazin H,, Reding R,, Otte JB,, Buts JP,, Sokal EM . 2002. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 73 : 1603 1610.[PubMed] [CrossRef]
33. Lee TC,, Goss JA,, Rooney CM,, Heslop HE,, Barshes NR,, Caldwell YM,, Gee AP,, Scott JD,, Savoldo B . 2006. Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection. Clin Transplant 20 : 689 694.[PubMed] [CrossRef]
34. Schubert S,, Renner C,, Hammer M,, Abdul-Khaliq H,, Lehmkuhl HB,, Berger F,, Hetzer R,, Reinke P . 2008. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients. J Heart Lung Transplant 27 : 100 105.[PubMed] [CrossRef]
35. Green M,, Bueno J,, Rowe D,, Mazariegos G,, Qu L,, Abu-Almagd K,, Reyes J . 2000. Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children. Transplantation 70 : 593 596.[PubMed] [CrossRef]
36. Gross TG . 2009. Treatment for Epstein-Barr virus-associated PTLD. Herpes 15 : 64 67.[PubMed]
37. San-Juan R,, Manuel O,, Hirsch HH,, Fernández-Ruiz M,, López-Medrano F,, Comoli P,, Caillard S,, Grossi P,, Aguado JM , ESGICH PTLD Survey Study Group, European Study Group of Infections in Compromised Hosts (ESGICH) from the European Society of Microbiology and Infectious Diseases (ESCMID) . 2015. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey. Clin Microbiol Infect 21 : 604e1 604e9.[PubMed] [CrossRef]
38. Gross T,, Orjuela MA,, Perkins SL,, Park JR,, Lynch JC,, Cairo MS,, Smith LM,, Hayashi RJ . 2012. Low-dose chemotherapy and rituximab for post-transplant disease (PTLD): A Children’s Oncology Group report. Am J Transplant 12 : 3069 3075.[PubMed] [CrossRef]
39. Savoldo B,, Goss JA,, Hammer MM,, Zhang L,, Lopez T,, Gee AP,, Lin YF,, Quiros-Tejeira RE,, Reinke P,, Schubert S,, Gottschalk S,, Finegold MJ,, Brenner MK,, Rooney CM,, Heslop HE . 2006. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 108 : 2942 2949.[PubMed] [CrossRef]
40. Ricciardelli I,, Brewin J,, Lugthart G,, Albon SJ,, Pule M,, Amrolia PJ . 2013. Rapid generation of EBV-specific cytotoxic T lymphocytes resistant to calcineurin inhibitors for adoptive immunotherapy. Am J Transplant 13 : 3244 3252.[PubMed] [CrossRef]
41. Ricciardelli I,, Blundell MP,, Brewin J,, Thrasher A,, Pule M,, Amrolia PJ . 2014. Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells. Blood 124 : 2514 2522.[PubMed] [CrossRef]


Generic image for table
Table 1

Cumulative 1- and 5-year incidence of PTLD in pediatric and adult SOT recipients by transplanted organ as reported in the 2010 Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients (OPTN/SRTR) Annual Report ( )

Citation: Nowalk A, Green M. 2016. Epstein-Barr Virus, p 127-134. In Hayden R, Wolk D, Carroll K, Tang Y (ed),

Diagnostic Microbiology of the Immunocompromised Host, Second Edition

. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.DMIH2-0011-2015

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error